Pharmacological companies may soon begin clinical trials of anti-IL-11 therapies on patients with idiopathic pulmonary fibrosis, a severe lung disease sharing several risk factors with COVID-19. Here, IL11 is linked to idiopathic pulmonary fibrosis.